The Journal of clinical endocrinology and metabolism · 2014
Effects of denosumab treatment and discontinuation on human growth plates.
Клинический случайСтатьяПоддержка NIH: внешняя программаResearch Support, N.I.H., IntramuralПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Howard D, Boyce Alison M, Tsai Jeffrey Y, Gafni Rachel I, Farley Frances A, Kasa-Vubu Josephine Z, Molinolo Alfredo A, Collins Michael T
Аннотация
CONTEXT: Denosumab is a humanized monoclonal antibody to receptor activator of nuclear factor-κB ligand used primarily for postmenopausal osteoporosis and skeletal-related events from metastatic cancer. Its safety in children has not been established.
OBJECTIVE: The objective of the study was to investigate the effects of denosumab treatment on skeletal growth and histology.
DESIGN: This was an observational case report with radiological and histopathological analyses.
SETTING: The study was conducted at a clinical research center.
PATIENTS: A 9-year-old boy with fibrous dysplasia treated with a 7-month course of denosumab participated in the study.
INTERVENTION: Histological analyses were performed and compared on growth plates from limbs that had been amputated before and 17 months after denosumab treatment.
MAIN OUTCOME MEASURES: Skeletal radiographs and bone histopathology from before and after treatment were measured.
RESULTS: After initiating denosumab, sclerotic metaphyseal bands appeared on radiographs. Posttreatment radiographs revealed migration of the bands away from the growth plates, consistent with continued linear growth. Histologically, the bands were composed of horizontally arranged trabeculae containing calcified cartilage. This cartilage appeared to derive from unresorbed primary spongiosa as a result of osteoclast inhibition by denosumab, similar to what has been observed with bisphosphonates. By 17 months after treatment, active bone resorption and formation had returned, as evidenced by the presence of active osteoclasts in resorption pits and osteoid surfaces.
CONCLUSIONS: Further studies are needed to determine the safety of denosumab on the growing skeleton. However, in this child there was continued epiphyseal activity both during and after treatment and reversal of bone turnover suppression after treatment discontinuation, suggesting that denosumab did not have significant adverse effects on growth.
OBJECTIVE: The objective of the study was to investigate the effects of denosumab treatment on skeletal growth and histology.
DESIGN: This was an observational case report with radiological and histopathological analyses.
SETTING: The study was conducted at a clinical research center.
PATIENTS: A 9-year-old boy with fibrous dysplasia treated with a 7-month course of denosumab participated in the study.
INTERVENTION: Histological analyses were performed and compared on growth plates from limbs that had been amputated before and 17 months after denosumab treatment.
MAIN OUTCOME MEASURES: Skeletal radiographs and bone histopathology from before and after treatment were measured.
RESULTS: After initiating denosumab, sclerotic metaphyseal bands appeared on radiographs. Posttreatment radiographs revealed migration of the bands away from the growth plates, consistent with continued linear growth. Histologically, the bands were composed of horizontally arranged trabeculae containing calcified cartilage. This cartilage appeared to derive from unresorbed primary spongiosa as a result of osteoclast inhibition by denosumab, similar to what has been observed with bisphosphonates. By 17 months after treatment, active bone resorption and formation had returned, as evidenced by the presence of active osteoclasts in resorption pits and osteoid surfaces.
CONCLUSIONS: Further studies are needed to determine the safety of denosumab on the growing skeleton. However, in this child there was continued epiphyseal activity both during and after treatment and reversal of bone turnover suppression after treatment discontinuation, suggesting that denosumab did not have significant adverse effects on growth.